

**Area Drugs and Therapeutics Committee Meeting Minutes**

18<sup>TH</sup> October 2023 10-11:30

Microsoft Teams Meeting

<b>Present:</b>	Mehrdad Malekian Victoria Gemmell (until 10:30) Gail Richardson (until 11:30) Mark Kirk Kelly Baillie (items 8 and 10 only) Stephanie Dundas Emma Harris Carol McGoff Christine Gilmour David Semple Colin Angus
<b>Apologies:</b>	<a href="#">Penny Brankin</a> , <a href="#">Kirsty MacFarlane</a> , <a href="#">Tyra Smyth</a>
<b>Declaration of Interest</b>	<b>NIL</b>

**Agenda**

Item	Notes	Action
<b>1</b>	<b><u>Minutes/Actions from the last meeting</u></b>  Both approved	
	<b>Matters arising not covered elsewhere on the agenda</b>	
<b>a.</b>	Ogluo-nil further received. Not approved. MM will feedback to author	<b>MM</b>
<b>b.</b>	IV Contrast-update Amendment made as requested. Document agreed.	<b>VG</b>
<b>c.</b>	Bijuve-nil further received Update not received as previously requested. Chair will feedback to author. Not approved.	<b>MM</b>
<b>d.</b>	Utrogestan-nil further received Update not received as previously requested. Chair will feedback to author. Not approved.	<b>MM</b>
<b>e.</b>	Psoriasis and Eczema Pathways-update awaited Previous amendments made as requested. Remove brand names and change to "bio-similars or equivalent" Approved pending this amendment.	<b>VG</b>

<p>f</p> <p>g</p> <p>h</p> <p>i</p> <p>j</p> <p>k</p>	<p>IV Fluids-update awaited Ongoing, updated expected next month.</p> <p>Topical Retinoids-Update This was discussed and agreed. Small point of clarification. Should read “accidental <i>foetal</i> exposure” in bullet point 2, but agreed pending this change</p> <p>Massive PE Guidance-Update Remains in progress</p> <p>Clinical Protocol-Kilsyri for Actinic Keratosis-update awaited Updated version accepted</p> <p>Renal-Clinical Protocols Patiromir (Veltassa), sodium zirconium (Lokelma) and Hyperkalaemia and potassium lowering Guidelines Acute Hyperkalaemia accepted – date of approval to be added Potassium lowering – accepted with minor amendments-unit of measurement to be added on pg 3</p> <p>Deprescribing Guideline The guideline was welcomed by the committee. Minor amendments were suggested and so it was requested that the final version be brought back to a future meeting. Suggested changes</p> <ul style="list-style-type: none"> <li>• Insert hyper link to OncPal guidelines</li> <li>• Remove requirement to check BP weekly</li> <li>• Remove requirement to monitor blood sugar weekly after discontinuation to monitor for symptomatic hyperglycaemia</li> <li>• The named point of contact for the guideline for future reference to be noted as the Lead Pharmacist for Medical Receiving at UHW and the Consultant for Palliative Care.</li> </ul> <p>Return for final review</p>	<p></p> <p><b>KM (VG)</b></p> <p><b>MM</b></p> <p><b>VG</b></p> <p><b>VG</b></p> <p></p>
<p>3</p>	<p><b><u>SMC Advice-CONFIDENTIAL</u></b></p> <p><b><u>Full Submissions</u></b></p> <ul style="list-style-type: none"> <li>• selpercatinib (Retsevmo) Eli Lilly and Company Ltd SMC2573 <b>Accepted Restricted with PAS Await advice from WoSCAN</b></li> <li>• efgartigimod alfa (Vyvgart) Argenx SMC2561 <b>Not Recommended</b> durvalumab (Imfinzi) AstraZeneca SMC2582 <b>Accepted with PAS Await advice from WoSCAN</b></li> <li>• pegunigalsidase alfa (Elfabrio) Chiesi Limited SMC2591 <b>Not Recommended</b></li> </ul>	<p></p>

	<ul style="list-style-type: none"> <li>avacopan (Tavneos) Vifor Fresenius Medical Care Renal Pharma SMC2578 <b>Accepted with PAS. Refer to Renal Service for comment.</b></li> </ul> <p><b><u>Resubmission</u></b></p> <ul style="list-style-type: none"> <li>mercaptopamine (Procysbi) Chiesi SMC2571 <b>Not Recommended</b></li> <li>tafamidis (Vyndaqel) Pfizer Limited SMC2585 <b>Accepted with PAS. FOR NOTING.</b></li> </ul> <p><b><u>Ultra Orphan</u></b> nil</p> <p><b><u>Abbreviated Submissions</u></b></p> <ul style="list-style-type: none"> <li>bimekizumab solution for injection in pre-filled syringe and pre-filled pen (Bimzelx®) UCB Pharma Ltd SMC2605 <b>Accepted Restricted with PAS . Refer to Rheumatology Service for comment.</b></li> </ul> <p><b><u>Non Submission</u></b></p> <ul style="list-style-type: none"> <li>progesterone vaginal capsules (Utrogestan®) Besins Healthcare UK Ltd SMC2630</li> </ul> <p><b><u>Deferred Advice</u></b> <u>risankizumab (Skyrizi) AbbVie UK Limited SMC2534. Refer to Gastroenterology Service for comment.</u></p> <p><b><u>Amended Advice</u></b> <u>olaparib film-coated tablets (Lynparza®) AstraZeneca UK Ltd SMC2518</u> <u>regorafenib film-coated tablets (Stivarga®) Bayer Plc. SMC2562</u></p> <p><u>Ibrutinib film-coated tablets (Imbruvica) Janssen-Cilag Ltd SMC2543</u> SMC has been made aware of an error in SMC2543 ibrutinib in combination with venetoclax for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). The dosing escalation of venetoclax was incorrectly described in section 1.1 and table 2.1 and incorrect costs calculated in table 9.1. An updated version is attached. <b>Please destroy any copies of the original advice and use the attached or refer to the updated version on the SMC website.</b></p> <p><b>All noted</b></p>	
4.	<p><b><u>SMC follow up</u></b></p> <p>CM talked the Committee through the SMC follow up which had been previously circulated. Feedback on semaglutide (Wegovy®) was given. Feedback on a number of items is expected in due course</p>	CM
5.	<p><b><u>Lanarkshire Formulary</u></b></p> <p>CM updated the Committee.</p>	CM

	<p>The preferred biosimilar of adalimumab is not moving to Hyrimoz<sup>®</sup> as planned due to supply chain issues. It was discussed that in Chapter 10, the adalimumab entry should be changed to add 'or equivalent biosimilar', in light of previous discussion above on the Eczema and Psoriasis pathway.</p> <p>Work is ongoing with the nausea and vomiting and substance misuse section of the Formulary; it is hoped that the substance misuse section can be brought to the next meeting.</p>	
6. (a)	<p><b><u>Clinical Protocols</u></b> Tezepelumab protocol Accepted</p>	VG
7.	<p><b><u>ADTC New Medicines Decisions</u></b>  Noted and accepted</p>	
8. (a)	<p><b><u>Unlicensed Medicines</u></b> Epoetin beta and Darbepoietin anti-thrombin- UPDATE Update provided by K Baillie at the start of the meeting Chair will review and authorise</p>	MM
9.	<p><b><u>Medication and Clinical risk in Lanarkshire</u></b> <a href="https://www.gov.uk/drug-safety-update">https://www.gov.uk/drug-safety-update</a> The risk associated with the prescribing of <b>Fluoroquinolone antibiotics: suicidal thoughts and behaviour was highlighted.</b> AMT have this on their workplan and guidelines will be updated. This is an issue for all prescribers of these antibiotics. Scriptswitch message to be considered to prompt clinicians at point of prescribing.</p>	CMcG
10.	<p><b><u>Regional Cancer Advisory Network</u></b> KB gave an update on these items</p>	
11.	<p><b><u>Patient Safety Alerts</u></b> NIL</p>	
12.	<p><b><u>Lay member related items</u></b> A concern regarding the matter of medicines' waste. Committee members gave reassurance that this being taken forward by the Partnership and Acute Medicines Management Boards and that various projects are being taken forward across NHSL acute and primary care services. These activities are being coordinated to ensure that there is a harmonized approach across the Board.</p>	
13. (a)  (i)	<p><b><u>Correspondence</u></b> <b><u>ADTC Collaborative</u></b>  <b><u>ADTC Collaborative (ADTCC Forum-any updates post meeting. Prof Sec attends)</u></b></p>	

	<p><b>For information - NHS Pharmacy First Scotland Approved List - Consensus Meeting Outcomes update</b> Noted</p> <p><b>(ii) Antimicrobial Management Committee ToR and Reporting Structure</b> Noted – welcomed as this gives a structure re the focus of AMT Request to update document to reflect recent personnel changes</p>	SD
<b>14.</b>	<p><b>Pharmacy &amp; NMAHP Prescribing Governance</b> nil</p>	
<b>15.</b>	<p><b><u>AOCB</u></b> <b>a.</b> Formulary Amendment Form The existing formulary request form is being updated. It was agreed that applicants must give an indication of the cost of any formulary amendment. The committee discussed how the financial aspects of formulary changes and broader decisions related to the ADTC are considered and managed. It was acknowledged that the financial implications, as well as the associated financial planning for medications, fall within the remit of the Partnership and Acute Medicine Management Boards (PMMBs) and not the ADTC. Nevertheless, there is a clear necessity to establish a formal connection between the ADTC and the PMMBs regarding this matter. It was suggested that the ADTC minutes should be routinely shared with the respective chairs of the Acute and Partnership PMMBs. Dr. Malekian, as the Chair of ADTC, will raise this with the Chairs of both PMMBs.</p>	MM
<b>16.</b>	<p><b><u>Date of next meeting</u></b>  Wednesday 15<sup>th</sup> November 2023 10-11:30 <a href="#">MS TEAMS</a></p>	